Drug intelligence / Profile preview

L363,586

Development stage: Preclinical
Modality: Peptides
Administration: Unknown

Overview

L363,586 is a cyclic hexapeptide analog of somatostatin. It was studied for its effects on pancreatic graft function in dogs and is structurally related to the natural hormone somatostatin, which inhibits the release of several other hormones and has regulatory effects on endocrine and exocrine secretion. The compound acts as a somatostatin analog but with modifications that may alter its potency or duration of action compared to native somatostatin[2].

Targets

SSTR (Somatostatin receptors)

Beyond the preview

Go deeper on L363,586.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L363,586.

Explore the full profile